Skip to main content

Table 3 Effect of renal anemia by cinacalcet therapy

From: Restoration of renal anemia following therapy with etelcalcetide for refractory secondary hyperparathyroidism: a case report with mini-review

References Viana et al. [21] Battistella et al. [22] Fusaro et al. [23] Tanaka M et al. [4]
Number of patients 28 (M 12, F 16) 40 (M 21, F 19)
14 PD
18 HD
8 over-night HD
5(M 3, F 2) 1337 (M 800, F 537)
Years old Not listed 54.6 ± 14.2 65.9 ± 14.11 58.88 ± 11.78
Used drugs and initial doses Cinacalcet 30 mg/day Cinacalcet 30 mg/day Cinacalcet 212.6 ± 60 mg/week Cinacalcet dose unknown
Baseline iPTH (pg/mL) 716.9 ± 471.6 198 (153, 248) pmol/L 605 ± 150 340.00 (223.00–506.60)
Changed PTH (pg/mL) 307 ± 220.3 (1Y) 124 (79, 178) (3M)
116 (64, 180) (6M)
66 (42–136) (12M)
405.11 ± 50 (1Y) Not listed
Baseline Hb (g/dL) 11.88 ± 0.75 11.6 ± 1.3 11.24 ± 1.31 10.65 ± 1.09
Changed Hb (g/dL) 12.29 ± 0.98 (1Y) 11.8 ± 14 (3M)
12.1 ± 12 (6M)
11.6 ± 1.3 (12M)
12 ± 1.19 (1Y) Initial concentrationx1.1 (6M)
Baseline ESA doses Darbepoetin 0.042 μg/kg/ week/g/dL Darbepoetin 40 (20, 60)/week Darbepoetin 70 ± 26 μg/week Not listed
Changed ESA doses Darbepoetin 0.033 μg/kg /week/g/dL 30 (20, 60) (3M)
30 (14, 65) (6M)
24 (20, 56) (12M)
Darbepoetin 48 ± 24 μg/week Not listed
Baseline vitamin D doses Paricalcitol 7.2 ± 4.5 μg/week Calcitriol 0.125 μg/day Not listed Not listed
Changed vitamin D doses Paricalcitol 6.0 ± 4.1 μg/week Calcitriol 0.25 μg/day Not listed Not listed
  1. Changes in iPTH, Hb concentration, doses of ESA, and doses of vitamin D during control and treatment periods
  2. P < 0.05: A value that recognizes a significant difference (p < 0.05) with respect to the value of base line
  3. (3 M) cinacalcet therapy 3 months
  4. (6 M) cinacalcet therapy 6 months
  5. (12 M) cinacalcet therapy 6 months
  6. (1Y) cinacalcet therapy 1 year